Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and keeping the price target at $9.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Justin Walsh has given his Buy rating due to a combination of factors related to the promising developments in Actinium Pharmaceuticals’ ATNM-400. The preclinical data presented at the SNMMI Annual Meeting highlighted ATNM-400’s potential in treating advanced prostate cancer, particularly in models resistant to current treatments. The compound demonstrated significant anti-tumor activity and favorable tumor uptake, surpassing existing therapies like Lu-177-PSMA-617 and Ac-225-PSMA-617 in preclinical models.
Moreover, the rapid clearance of ATNM-400 from healthy tissues suggests a potentially safer profile, which is crucial for patient outcomes. Although further information is needed to fully understand the molecular target and potential market opportunity, the current data supports the potential of ATNM-400 as a promising therapeutic option. These factors collectively underpin Walsh’s Buy rating and the $9 price target for Actinium Pharmaceuticals.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.